Accordingly, contingency analyses accounting for TCGA GI molecular subtypes and the WHO classification scheme including molecular and clinical indicators, demonstrate that STAT3-high defines a patient cohort enriched in the mesenchymal and classical molecular subtypes, typifying highly aggressive and recurrent gliomas (Supplementary Table 1a). This evidence concerns the gene STAT3 and glioma.